Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05850091
Other study ID # 2023P000945
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date December 7, 2023
Est. completion date July 2027

Study information

Verified date May 2024
Source Massachusetts General Hospital
Contact Fangzhou Cheng
Phone (617)-643-4842
Email proact@mgb.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this double-blind randomized controlled trial is to determine how treatment with high intensity statin, low-dose colchicine, and their combination modulates progression and composition of coronary atherosclerosis in individuals with high polygenic risk for coronary artery disease.


Description:

The main question PROACT 2 aims to answer is whether and how single or dual targeting of cholesterol-lowering and inflammation modulates coronary plaque in individuals with high polygenic risk and subclinical coronary atherosclerosis. This is a double-blind randomized controlled trial of 200 individuals with high polygenic risk for coronary artery disease and subclinical plaque on coronary computed tomography angiography. Participants will be randomized into four equal treatment groups: group A receiving a placebo daily, group B receiving rosuvastatin 20mg daily, group C receiving colchicine 0.6mg daily, and group D receiving both rosuvastatin 20mg daily and colchicine 0.6mg daily. The primary outcome is change in total non-calcified plaque volume on coronary computed tomography angiography from baseline to one year. Multiple secondary plaque imaging and biomarker outcomes will be explored in this pilot mechanistic trial.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date July 2027
Est. primary completion date July 2026
Accepts healthy volunteers No
Gender All
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria: - Males and females between 40 and 75 years of age capable and willing to provide informed consent - Participant has high CAD PRS as defined on a clinical test - Participant with subclinical atherosclerosis defined as plaque visible on CCTA and causing <70% luminal stenosis Exclusion Criteria: - Participant with a history of cardiovascular disease, defined by a diagnosis of coronary artery disease, peripheral artery disease, or cerebrovascular disease - Participant with a history of Liver disease (cirrhosis, active hepatitis, or severe hepatic disease) or any of the following recent lab results and determined to be non-transient: alanine aminotransferase greater than 3 times the upper limit of normal or total bilirubin greater than 2 times the upper limit of normal (unless due to Gilbert syndrome) - Participant with estimated glomerular filtration rate <60 mL/min/1.73 m2 or creatinine greater than 2 times the upper limit of normal - Patient with history of an allergic reaction or significant sensitivity to iodinated contrast, colchicine, or statins - Patient currently taking LDL cholesterol lowering or anti- inflammatory medications including colchicine - Participants requiring regular drugs known to be potent CY2P inhibitors (eg. ketoconazole, clarithromycin) - Female patient who is pregnant, or breast-feeding or is considering becoming pregnant during the study - Participant with BMI = 40 kg/m2 - Participant unable to provide informed consent - Participant unable to hold breath for 10 seconds

Study Design


Intervention

Drug:
Rosuvastatin
Pharmacotherapy for reduction in LDL cholesterol level
Colchicine
Pharmacotherapy for inflammation inhibition
Placebo
Capsule with sugar pill that mimics active study drugs

Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Massachusetts General Hospital National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in total non-calcified plaque volume from baseline to one year The primary outcome of this study is the change in total non-calcified plaque volume between the two groups from baseline to one year. This outcome will be measured using coronary computed tomography angiography (CCTA) and reported in cubic millimeters (mm³). The comparison of the changes in non-calcified plaque volume will help assess the effectiveness of the intervention on plaque progression and composition. 1 year
Secondary Change in total plaque volumes from baseline to one year The change in the following plaque volumes will be compared between the two groups from baseline to one year: total plaque volume, total calcified plaque volume, and total low attenuation plaque volume. These volumes will be analyzed individually and reported in cubic millimeters (mm³). 1 year
Secondary Change in maximal luminal stenosis from baseline to one year The change in maximal luminal stenosis will be compared between the two groups from baseline to one year, reported as a percentage (%). 1 year
Secondary Change in calcium score from baseline to one year The change in calcium score will be compared between the two groups from baseline to one year, reported in Agatston units. 1 year
Secondary Change in number of high-risk features from baseline to one year The change in the number of high-risk features will be compared between the two groups from baseline to one year, reported as a count (number of features). 1 year
Secondary Change in fat attenuation index from baseline to one year The change in fat attenuation index will be compared between the two groups from baseline to one year, reported in Hounsfield units (HU). 1 year
Secondary Progression in non-calcified plaque volume from baseline to one year The proportion of participants who had progression in non-calcified plaque volume from baseline to one year (%) 1 year
Secondary Change in low-density lipoprotein cholesterol (LDL-C) from baseline to one year The change in low-density lipoprotein cholesterol (LDL-C) will be compared between the two groups from baseline to one year, reported in milligrams per deciliter (mg/dL). 1 year
Secondary Change in C-reactive protein (CRP) from baseline to one year The change in C-reactive protein (CRP) will be compared between the two groups from baseline to one year, reported in milligrams per liter (mg/L). 1 year
Secondary Change in Interleukin-6 and Interleukin-1 beta (IL-1ß) from baseline to one year The change in Interleukin-6 (IL-6) and Interleukin-1 beta (IL-1ß) will be compared between the two groups from baseline to one year. Both biomarkers will be analyzed individually and reported in picograms per milliliter (pg/mL). 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A